Therapeutic drug monitoring of imatinib – how far are we in the leukemia setting?-Reference-Cited by-同舟云学术

Therapeutic drug monitoring of imatinib – how far are we in the leukemia setting?

Published:2024-02-12 Issue:3 Volume:17 Page:225-234
ISSN:1751-2433
Container-title:Expert Review of Clinical Pharmacology
language:en
Short-container-title:Expert Review of Clinical Pharmacology

Author:

Buhl Rasmussen Anna Sofie¹,Andersen Christen Lykkegaard²,Weimann Allan³,Yang Tianwu⁴,Tron Camille⁵,Gandemer Virginie⁶,Dalhoff Kim⁷⁸,Rank Cecilie Utke²,Schmiegelow Kjeld¹⁸

Affiliation:

1. Department of Pediatrics and Adolescent Medicine, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark

2. Department of Hematology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark

3. Pediatric Oncology Research Laboratory, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark

4. Department of Drug Design and Pharmacology, University of Copenhagen, Copenhagen, Denmark

5. Department of Biological Pharmacology, Rennes University Hospital, Rennes, France

6. Department of Pediatric Hematology and Oncology, Rennes University Hospital, Rennes, France

7. Department of Clinical Pharmacology, Copenhagen University Hospital, Bispebjerg, Copenhagen, Denmark

8. Institute of Clinical Medicine, Faculty of Medicine, University of Copenhagen, Copenhagen, Denmark

Funder

Engineer Otto Christensen’s Fond

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/17512433.2024.2312256

Reference93 articles.

1. Maintenance therapy for acute lymphoblastic leukemia: basic science and clinical translations

2. Cancer Chemotherapy: The Case for Therapeutic Drug Monitoring

3. Non-infectious chemotherapy-associated acute toxicities during childhood acute lymphoblastic leukemia therapy

4. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia

5. Review of therapeutic drug monitoring of anticancer drugs part two – Targeted therapies